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Control of Peroxisome Proliferator-Activated
Receptor ␥2 Stability and Activity by
SUMOylation
Z. Elizabeth Floyd and Jacqueline M. Stephens

Abstract
FLOYD, Z. ELIZABETH AND JACQUELINE M.
STEPHENS. Control of peroxisome proliferator-activated
receptor ␥2 stability and activity by SUMOylation. Obes
Res. 2004;12:921–928.
Objective: To determine whether small ubiquitin-related
modifier (SUMO)ylation of lysine 107 plays a role in regulating the activity of peroxisome proliferator-activated receptor ␥ (PPAR␥).
Research Methods and Procedures: Transient expression
of wild-type and K107R-PPAR␥2 in the NIH 3T3 fibroblast
cell line was carried out in conjunction with half-life studies, luciferase activity assays, and indirect immunofluorescence localization studies. Additional in vitro analysis was
carried out using recombinant SUMOylation pathway proteins along with in vitro transcribed and translated wild-type
or K107R-PPAR␥2 to examine the SUMO-1 modification
state of wild-type and SUMO-deficient K107R-PPAR␥2.
Results: While examining PPAR␥2 for potential ubiquitylation sites, we identified a strong consensus site for SUMO
modification that contains lysine 107. In vitro, SUMOylation studies showed that lysine 107 of PPAR␥2 is a major
SUMOylation site and that at least one other SUMOylation
site is present in PPAR␥. In addition, our results demonstrated that SUMO-1 affects PPAR␥ stability and transcriptional activity but not the nuclear localization of PPAR␥.
Discussion: These results indicated that SUMOylation
plays a role in regulating PPAR␥, both indirectly and directly by modification of lysine 107. Because PPAR␥ is
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regulated in numerous animal models of obesity, understanding the covalent modifications of PPAR␥ may enhance
our understanding of the metabolic syndrome.
Key words: fat cells, adipocytes, peroxisome proliferator-activated receptor ␥, small ubiquitin-related modifier-1, ubiquitin

Introduction

The peroxisomal proliferator-activated receptor ␥
(PPAR␥)1 is a member of the nuclear hormone receptor
superfamily that is essential for the development of adipocytes (1). PPAR␥ protein is expressed in adipocytes in two
forms, PPAR␥2 and PPAR␥1, that are produced by a combination of alternative promoter usage and alternative splicing (2,3). PPAR␥1 is expressed at low levels in multiple
tissues, whereas PPAR␥2 is expressed predominantly in fat
cells and differs from PPAR␥1 by an N-terminal extension
of 30 amino acids (4). As a member of the nuclear hormone
receptor family, PPAR␥ is composed of an N-terminal region
or activation function (AF)-1 domain followed by the DNA
binding and hinge domains. The carboxy-terminal or AF-2
domain is composed of a dimerization and ligand-binding
domain and is responsible for ligand-dependent activation (5).
Recent studies have focused on understanding the underlying mechanisms that regulate the activity of the nuclear
hormone receptors. In particular, the ubiquitin-proteasome
system has emerged as an important regulator of nuclear
receptors, including PPAR␥ (6 – 8). Moreover, a growing
number of studies have also shown a role for the ubiquitinlike protein, small ubiquitin-like modifier (SUMO), in regulating nuclear receptors (9 –13). SUMO conjugation
(SUMOylation) to a substrate occurs by a pathway that is

1
Nonstandard abbreviations: PPAR␥, peroxisomal proliferator-activated receptor ␥; AF,
activation function; SUMO, small ubiquitin-related modifier; RXR, retinoid ⫻ receptor;
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; GR, glucocorticoid
receptor.
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distinct from ubiquitin conjugation and functions to alter the
substrate’s cellular location, stability, or activity (14,15).
SUMOylation of the progesterone receptor (9,10), glucocorticoid receptor (12,16), and androgen receptor (11) at the
N-terminal AF-1 domain has been shown to alter transcriptional activity, indicating a general role for SUMOylation in
controlling the transcriptional activity of nuclear hormone
receptors.
We found that PPAR␥ contains a strong consensus site
for SUMOylation in the AF-1 domain that contains lysine
107. We now report that SUMOylation plays a role in
PPAR␥ stability and transcriptional activity and that lysine
107, a major SUMOylation site, is a determinant of PPAR␥
activity and stability.

Research Methods and Procedures
Materials
Dulbeccos’ modified Eagle’s medium and OptiMEM
were purchased from Invitrogen (Carlsbad, CA). Calf serum
was purchased from Atlanta Biological (Atlanta, GA).
PPAR␥ monoclonal (E-8, sc-7273), PPAR␥ polyclonal (H100, sc-7196), retinoid ⫻ receptor (RXR)␣ polyclonal (D20, sc-553), and ubc9 polyclonal (H-81, sc-10,759) antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). MG132 (N-carbobenzoxyl-Leu-Leu-Leucinal)
was purchased from Boston Biochemicals (Cambridge,
MA). A luciferase assay system, pSV-␤-galactosidase control vector, and ␤-galactosidase enzyme assay kit, as well as
the TnT T7 coupled reticulocyte lysate system, were obtained from Promega (Madison, WI). Polyfect was purchased from Qiagen (Valencia, CA), and the Quick-Change
Mutagenesis kit was obtained from Stratagene (La Jolla,
CA). The in vitro SUMOylation kit was obtained from LAE
Biotechnology (Rockville, MD).
Cell Culture and Mutagenesis
NIH 3T3 cells were cultured in Dulbeccos’ modified
Eagle’s medium supplemented with 10% calf serum and
antibiotics (100 units/mL penicillin G and 100 g/mL
streptomycin). The cells were maintained at 37 °C. The
pSVSportPPAR␥2-K107R and pSVSportPPAR␥2-K329R
were generated from wild-type PPAR␥2 by site-directed
mutagenesis according to the manufacturer’s directions
(Stratagene), and the mutations were confirmed by dideoxysequencing.
Transient Transfections and Immunoblotting
NIH 3T3 cells were grown to 30% confluence, and transfections were carried out using a total of 1.5 g DNA/well
and Polyfect according to the manufacturer’s directions
(Qiagen). Cells were assayed 48 hours after transfection.
Whole cell lysates were rinsed once with phosphate-buffered saline (pH 7.4) and harvested in a lysis buffer containing 10 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EGTA,
922
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1 mM EDTA, 1% Triton X-100, 0.5% Igepal, 1 M phenylmethylsulfonylfluoride, 1 M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 M leupeptin, and 2 mM
sodium vanadate. Lysates were analyzed by separation on
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli (17), followed
by immunoblotting as previously described (8).
SUMOylation Assay
Wild-type PPAR␥2, K107R-PPAR␥2, and RXR␣ were
transcribed and translated in vitro according to the manufacturer’s suggestions (Promega). Both forms of PPAR␥2
were labeled with [35S] Met (Amersham, Piscataway, NJ)
during translation, and RXR␣ was translated in the presence
of unlabeled methionine. Translation of both forms of
PPAR␥2 was confirmed by autoradiography, and translation of RXR␣ was confirmed by Western blot analysis. The
in vitro SUMOylation assays were carried out according to
the manufacturer’s instructions. In addition, ATP was added
fresh for a final concentration of 2 mM in each assay. The
reactions were analyzed by 10% SDS-PAGE followed by
autoradiography.
Immunolocalization
HeLa cells were transfected with pSVSport-PPAR␥2
wild-type or pSVSport-K107R-PPAR␥2 and cotransfected
with pSVSport-PPAR␥2 wild-type and pCMVubc9C93S
(ubc9DN). Twenty-four hours later, localization of both
forms of PPAR␥2 was determined by indirect immunofluorescence with monoclonal anti-PPAR␥ (Santa Cruz), and
localization of ubc9DN was assayed using a polyclonal
antiubc9 (Santa Cruz). Secondary antibodies were AlexaProbe 568 (goat anti-mouse) and 488 (goat anti-rabbit)
(Molecular Probes, Eugene, OR). Images were photographed using a Nikon Microphot-FXA microscope.
Stability of PPAR␥2 in Vivo
Experiments using transiently transfected NIH 3T3 cells
were carried out in the presence or absence of cycloheximide (5 M) to examine the half-life of the wild-type,
K107R, and K329R forms of PPAR␥2. When examining
the role of SUMOylation in PPAR␥2 stability, wild-type
and K107R-PPAR␥2 were cotransfected with a dominant
negative ubc9, pCMVubc9C93S (ubc9DN) (18), in the
presence or absence of MG132 (10M) as a proteasome
inhibitor.
Pulse-chase analysis of wild-type and the K107R form of
PPAR␥2 was carried out in NIH 3T3 cells at 24 hours after
transfection. Cells were transfected with either pSVSportPPAR␥2 or pSVSportK107R-PPAR␥2 and were metabolically labeled with [35S] Met/Cys (Perkin-Elmer, Boston,
MA) for 30 minutes in media devoid of exogenous methionine and cysteine. The cells were washed and chased in
complete media containing unlabeled methionine and cys-
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Figure 1: Schematic of PPAR␥2. Lysine 107 of the AF-1 domain
is contained in the consensus sequence for SUMO modification.
Lysine 107 is also in close proximity to serine 112, which plays a
role in PPAR␥ activation. Lysine 329 is located in the ligandbinding domain of PPAR␥ and has been implicated in PPAR␥
transcriptional activity (20).

teine and harvested at the indicated time-points. Cells were
resuspended in lysis buffer as described above and sonicated. After centrifugation, the resulting supernatant was
precleared by incubation with protein A-Sepharose (RepliGen, Waltham, MA) at 4 °C for 1 hour. Immunoprecipitations were performed by incubation with polyclonal antiPPAR␥ antibody (2 g, H-100; Santa Cruz,) followed by
incubation with protein A-Sepharose. The beads were
washed extensively, and the immunoprecipitates were analyzed by 10% SDS-PAGE followed by autoradiography.
Transcriptional Activity Assay
Wild-type or K107R-PPAR␥2 was transfected into NIH
3T3 cells along with pPPREx3TK-luciferase (19) and pSV␤-galactosidase and, where indicated, ubc9DN. An equal
amount of each construct was transfected into the cells, with
empty vector used to balance the total amount of DNA in
each case. Forty-eight hours later, PPAR␥2 was activated
by the addition of 5 M darglitazone in the presence or
absence of MG132 (10M). Whole cell extracts were harvested after 6 hours and analyzed for luciferase and ␤-galactosidase activity according to the manufacturer’s instructions (Promega). PPAR␥2 transcriptional activity is
reported as the ratio of luciferase activity (relative light
units) to ␤-galactosidase activity.

Results
Lysine 107 of the N-terminal AF-1 Domain Was a
Determinant of PPAR␥2 Stability
Recent reports have shown that PPAR␥ is targeted to the
ubiquitin-proteasome system for degradation under basal
and ligand-activated conditions (7,8). In an effort to understand how PPAR␥ degradation is regulated, we began a
systematic search for regions of PPAR␥2 that are required
for targeting to the ubiquitin-proteasome pathway. In particular, we were interested in determining which lysine(s)

Figure 2: The K107R form of PPAR␥2 is less stable than wildtype. The K107R, K329R, and wild-type forms of PPAR␥2 were
transiently transfected into NIH 3T3 cells. (A and B) Forty-eight
hours after transfection, the cells were incubated with 5 M
cycloheximide (CHX) and harvested at the indicated time-points.
Whole cell extracts were examined for PPAR␥2 expression by
Western blot analysis. A lane containing whole cell extract from
3T3-L1 adipocytes (L1-Ad) is included as a marker for PPAR␥1
and PPAR␥2. (C) Transfected NIH 3T3 cells were metabolically
labeled with [35S] Met/Cys, washed extensively, and chased in
media containing unlabeled Met/Cys. At the indicated time-points,
the cells were harvested and subjected to immunoprecipitation.

are targeted for ubiquitylation. As shown in Figure 1, 2
lysines from a total of 36 were initially chosen for sitedirected mutagenesis. Lysine 329 of PPAR␥2 (numbered
based on GenBank accession BCO21798), located in helix
3 of the AF-2 ligand-binding domain (5), is highly conserved in nuclear receptors and may play a role in coactivator binding and transcriptional activity (20). Lysine 107
of PPAR␥2 is located in the N-terminal AF-1 domain in
close proximity to serine 112 and is contained in a strong
consensus sequence for SUMO recognition, KXE (where
 is a hydrophobic residue) (21,22). SUMOylation has been
shown to directly affect ubiquitylation in the case of IB-␣
and Mdm2 (15). As shown in Figure 2, half-life experiments
carried out in the presence of cycloheximide indicated that
substitution of arginine for lysine 329 had no effect on the
turnover of PPAR␥2, whereas the K107R mutated form of
PPAR␥2 was more labile than wild-type. Using pulse-chase
experiments, we confirmed that the K107R form of
PPAR␥2 is less stable than wild-type PPAR␥2. The increased decay rate indicated that lysine 107 of PPAR␥2 was
not conjugated to ubiquitin but did have a modest effect on
the stability of PPAR␥2.
PPAR␥ Was SUMOylated at Lysine 107 in Vitro
Based on the results shown in Figure 2, we hypothesized
that SUMOylation of PPAR␥ at lysine 107 is a determinant
OBESITY RESEARCH Vol. 12 No. 6 June 2004
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Figure 3: PPAR␥ is SUMOylated at lysine 107. Wild-type
PPAR␥2 and K107R-PPAR␥2 were 35S-labeled through in vitro
transcription/translation (Promega) reactions. RXR␣ was generated by in vitro transcription/translation without 35S-labeling. The
presence of RXR␣ was confirmed by Western blotting. (A) Wildtype PPAR␥2 was incubated in buffer only (⫺) or in the presence
(⫹) of SAEI/II (E1), ubc9 (E2), and SUMO-1 at 37 °C for 1 hour.
RXR␣ was included in the reaction as indicated. (B) Wild-type
PPAR␥2 or K107R-PPAR␥2 was incubated at 37 °C for 1 hour in
buffer only (⫺) or in the presence (⫹) of SAEI/II, ubc9, and
SUMO-1. In each reaction, ATP was added fresh to yield a final
concentration of 2 mM ATP.

of PPAR␥ stability. To confirm that PPAR␥ is SUMOylated
at lysine 107, we carried out an in vitro SUMOylation
experiment using 35S-labeled PPAR␥2 wild-type in the
presence of SUMO-1, along with ubc9, the essential E2, and
SAEI/SAEII, the SUMO-activating enzyme (E1) (14). As
shown in Figure 3A, several higher molecular weight bands
were apparent when wild-type PPAR␥ was incubated in the
presence of the SUMOylation enzymes, indicating that
PPAR␥ was modified by SUMO-1 in vitro. The most prominent bands were consistent with the addition of one or two
SUMO-1 proteins. The presence of RXR␣ may increase the
efficiency of PPAR␥ SUMOylation, but RXR␣ is not required for PPAR␥ SUMOylation in vitro. Figure 3B shows
that replacement of lysine 107 with arginine resulted in the
loss of the higher molecular weight bands along with the
greatly decreased intensity of the band corresponding to the
addition of a single SUMO-1. This is consistent with lysine
107 being a direct target of the SUMOylation machinery
and the primary SUMO-1 site in PPAR␥2. However, at least
one other nonconsensus site in PPAR␥ was modified by
SUMO-1, albeit at reduced levels in the in vitro experiment.
SUMOylation Did Not Alter Localization of PPAR␥2 to
the Nucleus
To determine whether SUMOylation affects the cellular
localization of PPAR␥, we carried out indirect immunolocalization experiments with wild-type PPAR␥2 in the presence or absence of the dominant negative form of ubc9
(ubc9DN). In addition, we compared the nuclear localization of wild-type PPAR␥2 with the K107R form of
PPAR␥2. The experiments shown in Figure 4 indicated that
both wild-type PPAR␥2 and K107R-PPAR␥2 were located

Figure 4: SUMOylation did not alter localization of PPAR␥2 to the nucleus. HeLa cells were transfected with pSVSport-PPAR␥2 wild-type
or pSVSport-K107R-PPAR␥2 (A) or cotransfected with pSVSport-PPAR␥2 wild-type and pCMVubc9DN (B). Twenty-four hours later,
localization of both forms of PPAR␥2 was determined by indirect immunofluorescence. AlexaProbe 568 (rhodamine) secondary antibody
was used to detect both forms of PPAR␥2, and AlexaProbe 488 (fluorescein) was used to detect ubc9DN. The overlap of wild-type PPAR␥2
and ubc9DN in the nucleus appears orange in B. Images were photographed using a Nikon Microphot-FXA microscope.
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Figure 5: Wild-type-PPAR␥2 and K107R-PPAR␥2 decay rates
were higher in the presence of ubc9DN. Transient transfections of
wild-type and K107R-PPAR␥2 alone or in the presence of
ubc9DN were carried out in NIH-3T3 cells. After forty-eight
hours, the cells were incubated with 5 M cycloheximide (CHX)
and 10 M MG132 where indicated, harvested at the indicated
time-points, and subjected to Western blot analysis.

in the nucleus. In addition, cotransfection of wild-type
PPAR␥2 with ubc9DN did not alter the nuclear localization
of PPAR␥2, indicating that SUMOylation was not required
for localizing PPAR␥ to the nucleus. However, this result
cannot rule out the possibility that SUMOylation can affect
the subnuclear localization of PPAR␥.
SUMOylation Affected PPAR␥2 Stability
To examine the role of SUMOylation in PPAR␥2 turnover, we examined the decay rate of both wild-type
PPAR␥2 and K107R-PPAR␥2 in the presence or absence of
ubc9DN, a dominant negative form of the essential conjugating enzyme (E2) for SUMO modification (18). Figure 5
shows that the steady-state levels of wild-type PPAR␥2
were decreased in the presence of ubc9DN, whereas the
levels of K107R-PPAR␥2 were unchanged. However, the
turnover rate of both forms of PPAR␥2 was significantly
increased in the presence of ubc9DN, suggesting that lysine
107 was not the only possible SUMOylation site in PPAR␥
or that the effect was due to disruption of SUMOylation of
an interacting factor that influences PPAR␥ turnover. In
addition, the increased turnover rate introduced by inhibiting SUMOylation was abrogated in the presence of MG132.
This indicates that SUMOylation may function, in part, to
regulate targeting of PPAR␥ to the 26S proteasome.
SUMOylation Affected the Transcriptional Activity of
PPAR␥2
SUMOylation has been shown to regulate protein activity, as well as protein stability and cellular localization (15).
Recent studies have revealed that SUMOylation is involved

in regulating the transcriptional activity of several members
of the nuclear hormone receptor superfamily (10,12,13). We
examined the transcriptional activity of wild-type PPAR␥2
and K107R-PPAR␥2 in the absence or presence of ubc9DN
to block SUMOylation (Figure 6). For each condition, the
cells were treated with darglitazone, a synthetic PPAR␥
ligand. As shown in Figure 6A, the transcriptional activity
of wild-type PPAR␥2 increased in the presence of ubc9DN,
indicating that SUMOylation acts to attenuate PPAR␥2
activity. Moreover, K107R-PPAR␥2 was more active than
wild-type PPAR␥2. The 2.6-fold increase in activity of
K107R-PPAR␥2 over wild-type PPAR␥2 (Figure 6B) under
control conditions was largely eliminated in the presence of
ubc9DN, suggesting that SUMO modification at lysine 107
is involved in determining PPAR␥2 activity. However, we
also observed that the increased activity obtained for wildtype PPAR␥2 in the presence of ubc9DN was greater that
the activity found in K107R-PPAR␥2 under control conditions. These results support the notion that additional nonconsensus SUMOylation sites are present in PPAR␥2 or
that SUMOylation of an interacting protein also influences
the transcriptional activity of PPAR␥2.
We also carried out these experiments in the presence or
absence of MG132 to examine the effect of proteasome
inhibition on PPAR␥2 activity. For both wild-type PPAR␥
and K107R-PPAR␥, proteasome inhibition was associated
with increased transcriptional activity (Figure 6), suggesting
a link between transcriptional activation and degradation, as
has been shown for a variety of transcription factors (23).

Discussion
Nuclear hormone receptors undergo an intricate set of
posttranslational modifications that modulate their function,
including phosphorylation, acetylation, and ubiquitylation.
Recent studies have shown that these receptors can also be
conjugated to SUMO-1, a small ubiquitin-like modifier
protein. To date, it has been shown that SUMOylation plays
a role in the transcriptional activity of the aryl hydrocarbon,
progesterone, glucocorticoid, and androgen receptors (16).
Our work indicated that SUMOylation also modulates the
stability and transcriptional activity of PPAR␥, a nuclear
receptor essential for the development of fat cells.
Like other nuclear receptors, PPAR␥ contains a strong
SUMOylation consensus site in the AF-1 domain at the
N-terminal region. We established that PPAR␥2 is
SUMOylated at lysine 107 and at least one other (nonconsensus) site. RXR␣, the heterodimeric PPAR␥ partner required for DNA binding, was not required for PPAR␥
SUMOylation in vitro, indicating that DNA binding may
not be essential for PPAR␥2 SUMOylation.
Substitution of lysine 107 (K107R) in the consensus site
resulted in increased PPAR␥ turnover, suggesting that, although lysine 107 is not an ubiquitylation site, it does play
a role in PPAR␥ stability, possibly through SUMOylation.
OBESITY RESEARCH Vol. 12 No. 6 June 2004
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Figure 6: SUMOylation and degradation affected PPAR␥2 transcriptional activity. Wild-type PPAR␥2or K107R-PPAR␥2 were transfected
into NIH-3T3 cells along with PPREx3-TK-luciferase, ␤-galactosidase, and, where indicated, ubc9DN. An equal amount of each construct
was transfected into the cells with empty vector (pBluescriptSK) used to balance the total amount of DNA in each case. Forty-eight hours
later, 5 M darglitazone (TZD) was added as a synthetic PPAR␥ ligand. Where indicated, the cells were preincubated for 1 hour with 10
M MG132 before the addition of darglitazone. Whole cell extracts were harvested after 6 hours. The experiment was independently
performed three times, and activity is reported in relative light units (RLU)/␤-galactosidase as (A) fold-increase of wild-type and
K107R-PPAR␥2 over background (wild-type PPAR␥2 without ligand) and (B) fold-increase of K107R over wild-type PPAR␥2. Activity
levels (black bars) were also measured to determine the contribution of ubc9DN or MG132 in the absence of either form of PPAR␥2.

Indeed, generalized inhibition of SUMOylation using a
dominant negative form of ubc9 destabilized both wild-type
and K107R-PPAR␥2. However, proteasome inhibition abrogated the increased turnover of PPAR␥ observed in the
presence of the dominant negative form of ubc9, indicating
that SUMOylation either directly or indirectly affects targeting of PPAR␥ to the proteasome.
Our studies also showed that generalized inhibition of
SUMOylation resulted in increased PPAR␥ transcriptional
activity. Moreover, mutation of lysine 107 (K107R) enhanced PPAR␥ activity, indicating that lysine 107 acts as a
determinant of PPAR␥ activity. This supports the notion
that SUMOylation of lysine 107 plays a role in regulating
PPAR␥ transcriptional activity. Interestingly, we also observed that inhibition of the proteasome resulted in increased PPAR␥ transcriptional activity. This observation
suggests that SUMOylation and targeting to the proteasome
function to down-regulate PPAR␥ activity, although these
processes have opposite effects on the stability of PPAR␥.
This situation is similar to findings reported for the glucocorticoid receptor (GR) (24). In that case, it was shown
that GR-mediated transcriptional activity is down-regulated
926
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by the proteasome, whereas a separate study has found that
generalized SUMOylation both destabilizes GR and increases GR transcriptional activity (16).
The suggestion that SUMOylation of PPAR␥ attenuates
PPAR␥ transcriptional activity is consistent with other results showing that SUMOylation of the androgen receptor
(11) and GR (12) at N-terminal lysines results in decreased
transcriptional activity, as does SUMOylation of the progesterone receptor in the AF-1 domain (9,10). In these
studies, the influence of SUMOylation on the transcriptional activity of the receptors occurs in a promoter contextdependent manner. In each case, attenuation of activity is
associated with the presence of more than one response
element. In this study, the observed effects of SUMOylation
on PPAR␥ transcriptional activity were also measured in the
presence of more than one response element, and further
studies are planned to examine the importance of promoter
context in regulating PPAR␥ transcriptional activity. In this
context, it is important to note that an earlier study using
two copies of the PPAR␥ response element has shown that
amino acids 99 –129 of PPAR␥2 repress PPAR␥2 transcriptional activity (25).

SUMOylation of PPAR␥2, Floyd and Stephens

Moreover, recent studies have defined a motif in the
N-terminal region of the GR (26) and the CCAAT/enhancer-binding proteins ␣, ␤, ␦, and  (27,28) that inhibits
transcriptional activity. This motif also occurs in the otherwise divergent AF-1 domain of the nuclear receptors and
has been named the synergy control motif by Iniguez-Lluhi
and Pearce (26) because of its role in regulating higher order
interactions of the identified transcription factors. These
studies have shown that the synergy control motif overlaps
the consensus SUMOylation motif, and SUMOylation of
the conserved lysine is associated with transcriptional attenuation (26,28). This synergy control motif is also found in
the AF-1 domain of PPAR␥ and overlaps the SUMOylation
motif, which is near serine 112, a residue well known to
participate in the regulation of PPAR␥ transcriptional activity (29). Our findings suggested that this region of the
AF-1 domain of PPAR␥, as found in other nuclear hormone
receptors, modulates both transcriptional activity and
PPAR␥ stability and that SUMOylation plays a role in this
process.
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